After completing this activity, the participant should be better able to: Recognize the burden of CKD as a major driver of cardiovascular and renal morbidity and mortality in women Review conventional and women-specific risk factors for CKD progression in women Identify women at risk for kidney disease or kidney disease progression based on recommended diagnostic practices Review the efficacy and safety with SGLT2 inhibitors for patients with or at-risk for CKD Discuss practical considerations for the application of SGLT2 inhibitors to improve renal outcomes in women with or at-risk for CKD Select tailored treatment regimens that reduce the risk of renal and cardiovascular events in women with or at-risk for CKD
- Provider:Partners for Advancing Clinical Education (PACE)
- Activity Link: https://cme.tarsusmedicaleducation.com/cardiometabolic-health-congress-cmhc-/content/risk-stratification-and-treatment-chronic-kidney-disease-women-1729#group-tabs-node-course-default1
- Start Date: 2024-07-03 05:00:00
- End Date: 2024-07-03 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Boehringer Ingelheim Pharmaceuticals, Inc. - Amount: 118205.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest